Pfizer Inc has acquired a minority stake in privately-held AM-Pharma BV which has a Phase 2 product for acute kidney injury related to sepsis. The US company made an upfront payment of $87.5 million to AM-Pharma in early May for the stake, and also secured an exclusive option to buy the rest of the company.
